Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 3, 2014, Pages 425-435

  Quinn, Emma ^a   Jit, Mark ^b   Newall, Anthony T ^c  

^a Ministry of Health   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cost effectiveness; disease impact; economic evaluation; influenza; quadrivalent; vaccination

Indexed keywords

ENZIRA; FLUBOK; FLUVAL AB; IMUVAC; INFLUENZA VACCINE; QUADRIVALENT INFLUENZA VACCINE; TRIVALENT INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIROFLU; VIRUS VACCINE;

AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HEALTH CARE DISPARITY; HERD IMMUNITY; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; NONHUMAN; REVIEW; SEASONAL INFLUENZA; UNITED STATES; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; INFLUENZA; VACCINATION;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 84900817579     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.908713     Document Type: Review

References (72)

1. Fraaij PL, Heikkinen T. Seasonal influenza: the burden of disease in children. Vaccine 2011;29(43):7524-8
2. Antonova EN, Rycroft CE, Ambrose CS, et al. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health 2012;12:968
3. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011;378(9807):1917-30
4. Ruttimann RW, Bonvehi PE, Vilar-Compte D, et al. Influenza among the elderly in the Americas: a consensus statement. Rev Panam Salud Publica 2013; 33(6):446-52
5. Elliot AJ, Fleming DM. Influenza and respiratory syncytial virus in the elderly. Expert Rev Vaccines 2008;7(2):249-58
6. Lang PO, Mendes A, Socquet J, et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging 2012;7: 55-64
7. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25(27):5086-96
8. Jit M, Newall AT, Beutels P. Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Hum Vaccin Immunother 2013;9(4): 834-40
9. Carrillo-Santisteve P, Ciancio BC, Nicoll A, Lopalco PL. The importance of influenza prevention for public health. Hum Vaccin Immunother 2012;8(1):89-95
10. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62
11. Poland GA, Morse D. Improving the public health: the USA recommendation for universal influenza immunization. Vaccine 2010;28(16):2799-800
12. JCVI, Statement on the annual influenza vaccination programme-extension of the programme to children, 25 July 2012., Department of Health: joint Committee on Vaccination and Immunisation, Editor. DH, England; 2012. Available from: http://www.wp.dh.gov.uk/transparency/files/2012/07/JCVI-statement-on-the- annual-influenza-vaccinationprogramme-25-July-2012.pdf
13. Ellebedy AH, Webby RJ. Influenza vaccines. Vaccine 2009;27(Suppl 4):D65-8
14. Nichol KL, Treanor JJ. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006;194(Suppl 2):S111-18
15. WHO. Recommendations for the production and control of influenza vaccine (inactivated). WHO Technical Report Series No. 927, Annex 3, W.H. Organisation, Editor. 2006. Available from: http://www.who.int/biologicals/publications/trs/ areas/vaccines/influenza/ANNEX%203% 20InfluenzaP99-134.pdf [Last accessed 17 August 2013]
16. Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010;85(3):257-73
17. Russell CA, Jones TC, Barr IG, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008;26(Suppl 4): D31-4
18. WHO writing group. Ampofo WK, Baylor N, et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters Geneva, Switzerland, 14-16 June 2010. Influenza Other Respi Viruses 2012;6(2): 142-52.e1-5
19. Rodewald LE, Orenstein WA, Mason DD, Cochi SL. Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention. Clin Infect Dis 2006;42(Suppl 3):S104-10
20. Jefferson T, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012;8:CD004879
21. Jefferson T, Rivetti D, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010(2):CD001269
22. Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since. 1983;Virology 1990;175(1):59-68
23. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013;11:153
24. Richard SA, Viboud C, Miller MA. Evaluation of Southern Hemisphere influenza vaccine recommendations. Vaccine 2010;28(15):2693-9
25. Barr IG, Komadina N, Durrant C, et al. Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since. 2000;Commun Dis Intell Q Rep 2006;30(3):350-7
26. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012;8(1): 81-8
27. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 2012;72(17): 2177-85
28. Rota PA, Hemphill ML, Whistler T, et al. Antigenic and genetic characterization of the haemagglutinins of recent cocirculating strains of influenza B virus. J Gen Virol 1992;73(Pt 10):2737-42
29. Centre for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older-USA, 2013. MMWR Morb Mortal Wkly Rep 2013;62(Suppl 1:1) Available from: http://www.cdc.gov/mmwr/pdf/ other/su6201.pdf
30. Kieninger D, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >=18 years. BMC Infect Dis 2013;13(1):343
31. Langley JM, Carmona Martinez A, Chatterjee A, et al. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: a Phase III Randomized Controlled Trial in Children. J Infect Dis 2013;208(4):544-53
32. Beran J, Peeters M, Dewé W, et al. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infect Dis 2013;13:224
33. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis 2013; 207(12):1878-87
34. Greenberg DP, Robertson CA, Noss MJ, et al. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine 2013; 31(5):770-6
35. Block SL, Falloon J, Hirschfield JA, et al. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J 2012;31(7):745-51
36. Toback SL, Levin MJ, Block SL, et al. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. Expert Rev Vaccines 2012;11(11):1293-303
37. Belshe RB.The need for quadrivalent vaccine against seasonal influenza. Vaccine 2010;28(Suppl 4):D45-53
38. Dolin R. The quadrivalent approach to influenza vaccination. J Infect Dis 2013; 208(4):539-40
39. Vodeiko GM, et al. Genetic and phenotypic analysis of reassortants of high growth and low growth strains of influenza B virus. Vaccine 2003;21(25-26):3867-74
40. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine 2012; 30(52):7443-6
41. Meier G. Universal mass vaccination with quadrivalent influenza vaccine (QIV) in the USA. In: ISPOR 18th Annual International Meeting, PIN79; International Society for Pharmaeconomics and Outcomes, New Orleans, LA, USA; 2013
42. Meier G. Potential benefits analysis of quadrivalent influenza vaccine (QIV) on influenza disease burden in the UK, year by year analysis. In: ISPOR 18th Annual International Meeting PIN57; International Society for Pharmacoeconomics and Outcomes, New Orleans, LA, USA; 2013
43. Pitman R, Nagy LD, Math M, et al. Cost-effectiveness comparison of quadrivalent vs trivalent influenza vaccines in the USA. In: ISPOR 18th Annual International Meeting; New Orleans; LA, USA; 2013
44. Pitman R, Nagy L, Scott D. Cost effectiveness of quadrivalent influenza vaccination in England and Wales, in Options for Control of Influenza. International Society for Influenza and Other Respiratory Viruses (ISIRV); Cape Town, South Africa; 2013
45. Eichner M, Schwehm M, Knuf M, et al. 4Flu-an individual-based simulation tool to study the effects of vaccination on seasonal influenza in Germany. In: Options for Control of Influenza, International Society for Influenza and other Respiratory Viruses (ISIRV); Cape Town, South Africa; 2013; P1-192:140-1
46. de Boer P, Crépey P, Pitman R, et al. on behalf of the Global Influenza Initiative: Cost effectiveness of a quadrivalent versus trivalent influenza vaccine in the United States. In: Options for Control of Influenza, International Society for Influenza and other Respiratory Viruses (ISIRV); Cape Town, South Africa; 2013;LBA-P2-056:667
47. Yang M, Tan C, Su J. Will QIV be more cost-effective than TIV in preventing Influenza in Taiwan?, in Options for the Control of Influenza. International Society for Influenza and Other Respiratory Viruses (ISIRV); Cape Town, South Africa; 2013
48. Thompson WW, Ridenhour BL, Barlie JP, Shay DK. Time-series analyses of count data to estimate the burden of seasonal infectious diseases. Epidemiology 2012;23(6): 839-42; discussion 843.4
49. Thompson WW, Comanor L, Shay DK. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 2006;194(Suppl 2):S82-91
50. Yang L, Chiu SS, Chan KP, et al. Validation of statistical models for estimating hospitalization associated with influenza and other respiratory viruses. PLoS One 2011;6(3):e17882
51. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine 2012; 30(11):1993-8
52. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza-USA, 1976-2007. MMWR Morb Mortal Wkly Rep 2010 59(33): 1057-62
53. Zhou H, Thompson W, Viboud C, et al. Hospitalizations associated with influenza and respiratory syncytial virus (RSV) in the US from the 1993-94 through 2005-06 seasons. In: Options for the control of influenza VII, International Society for Influenza and Other Respiratory Viruses (ISIRV); Hong Kong, China. 3-7th September 2010; 2010
54. Glezen WP, Schmier JK, Kuehn CM, et al. The Burden of Influenza B. A structured literature review. Am J Public Health 2013; 103(3):e43-51
55. Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis 2007;11(1):40-7
56. Bender JM, Ampofo K, Gesteland P, et al. Development and validation of a risk score for predicting hospitalization in children with influenza virus infection. Pediatr Emerg Care 2009;25(6):369-75
57. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the USA. JAMA 2003;289(2):179-86
58. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the USA. JAMA 2004;292(11):1333-40
59. Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of USA influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009;3(1): 37-49
60. Dushoff J, Plotkin JB, Viboud C, et al. Mortality due to influenza in the. USA-an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163(2):181-7
61. Pitman RJ, Melegaro A, Gelb D, et al. Assessing the burden of influenza and other respiratory infections in England and Wales. J Infect 2007;54(6):530-8
62. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the USA. 1993Clin Infect Dis 2012;54(10): 1427-36
63. Wu P, Goldstein E, Ho LM, et al. Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis 2012;206(12):1862-71
64. Yang L, Wang XL, Chan KP, et al. Hospitalisation associated with the 2009 H1N1 pandemic and seasonal influenza in Hong Kong, 2005 to 2010. Euro Surveill 2012;17(45):20317
65. Cromer D, van Hoek AJ, Jit M, et al. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. J Infect 2014;68(4): 363-71
66. Chaves SS, Aragon D, Bennett N, et al. Patients hospitalized with laboratory-confirmed influenza during the. 2010-2011. influenza season: exploring disease severity by virus type and subtype. J Infect Dis 2013;208(8):1305-14
67. Esposito S, Cantarutti L, Molteni CG, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. J Infect 2011;62(5): 379-87
68. Roos R. Quadrivalent flu vaccine coming; companies cite good demand. Centre for Infectious Diseases Research and Policy (CIDRAP) newsletter, 2013. Available from: http://www.cidrap.umn.edu/news-perspective/2013/08/quadrivalent- flu-vaccines-coming-companies-cite-good-demand; [Last accessed 5 August 2013]
69. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in. 2011;Vaccine 2013;31(5):728-31
70. WHO, Report of the second WHO Consultation on the Global Action Plan for Influenza Vaccines (GAP). WHO, Geneva, Switzerland, 2011. Available from: http://whqlibdoc.who.int/publications/2012/9789241564410-eng.pdf
71. Jefferson T, Di Pietrantonj C, Al-Ansary LA, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2010(2):CD004876
72. Pitman R, Fisman D, Zaric GS, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health 2012;15(6):828-34